TY - JOUR
T1 - Local treatment of liver metastases with recombinant tumour necrosis factor (rTNF)
T2 - A phase one study
AU - IJzermans, J. N.M.
AU - Van Der Schelling, G. P.
AU - Scheringa, M.
AU - Splinter, T. A.W.
AU - Marquet, R. L.
AU - Jeekel, J.
PY - 1991/8/1
Y1 - 1991/8/1
N2 - Fifteen patients with therapy-resistant liver metastases were treated in a phase-I study with recombinant human TNF (rTNF). The rTNF was injected into one liver metastasis by ultrasound guidance, using a 50 μg escalating dose schedule (3 patients/dosage) ranging from 100-350 μg/injection. Influenza-like symptoms like fever, chills, nausea and vomiting were the main clinical side effects. Two patients, treated concomitantly with rTNF and morphine, showed mild hypotension. Other toxicities, as reported after systemic use of rTNF, such as decrease in leukocyte and platelet counts, renal or liver toxicity were not observed. In eight patients growth arrest was observed in rTNF-treated metastases, whereas non-injected lesions showed growth progression. The maximum tolerated dose by this route of administration is > 350 μg/injection. Based on these observations it is concluded that the toxicity of rTNF injected into liver metastases by sonographic control is transient and mild and that intratumoural administration of rTNF might play a role in local tumour control.
AB - Fifteen patients with therapy-resistant liver metastases were treated in a phase-I study with recombinant human TNF (rTNF). The rTNF was injected into one liver metastasis by ultrasound guidance, using a 50 μg escalating dose schedule (3 patients/dosage) ranging from 100-350 μg/injection. Influenza-like symptoms like fever, chills, nausea and vomiting were the main clinical side effects. Two patients, treated concomitantly with rTNF and morphine, showed mild hypotension. Other toxicities, as reported after systemic use of rTNF, such as decrease in leukocyte and platelet counts, renal or liver toxicity were not observed. In eight patients growth arrest was observed in rTNF-treated metastases, whereas non-injected lesions showed growth progression. The maximum tolerated dose by this route of administration is > 350 μg/injection. Based on these observations it is concluded that the toxicity of rTNF injected into liver metastases by sonographic control is transient and mild and that intratumoural administration of rTNF might play a role in local tumour control.
UR - https://www.scopus.com/pages/publications/0025775716
UR - https://typeset.io/papers/local-treatment-of-liver-metastases-with-recombinant-tumour-1d0seocvcb
M3 - Article
C2 - 1944989
AN - SCOPUS:0025775716
SN - 0167-2487
VL - 43
SP - 121
EP - 125
JO - Netherlands Journal of Surgery
JF - Netherlands Journal of Surgery
IS - 4
ER -